Affymetrix - Fields of Study - Unraveling the Molecular Mechanisms of Cancer

Cancer is a highly complex disease, which can encompass multiple genomic alterations on the pathway from a normal cell to a diseased state. Over the past decade, research has increasingly distinguished how these genomic perturbations drive cancer cell survival by altering mechanisms for cell cycle control, differentiation, apoptosis, tumor vascularization and metabolism.

Point Mutations
Translocations
Gene Amplification/Loss
Epigenetic Modifications
Deletions
Altered Gene Expression

Affymetrix' GeneChip® products have proven to be powerful tools in unraveling the molecular mechanisms of cancer. This research is paving the way for improving cancer diagnosis, for patient stratification in prognostic and therapeutic decision-making, and for developing of safer and more efficacious treatments.

By providing a platform path from discovery research through signature validation to diagnostic commercialization, Affymetrix is enabling the translation of cancer research discoveries to clinical utility.

Learn more about how Affymetrix products are supporting:

Improved disease diagnosis

Prediction of clinical outcomes

Refinement of therapeutic decisions and predicting
drug efficacy

Target and biomarker discovery

Landmark Studies Using GeneChip® Technology

Golub, T.R., et al. Molecular classification of cancer: class discovery and class prediction by gen expression monitoring. Science. 1999, 286(5439),
531-7.

Hacia, J.G., et al. Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis. Nat Genet. 1996, 14(4): 441-7.

Landmark Studies Using GeneChip® Technology

Featured Products

Featured Support

Research Highlights

Microarray Bulletin

Affymetrix User Registration